Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first half of 2028, through expected proof-of-concept clinical readouts for each program Conference call and webcast to be held Tuesday, May 27 at 8:00 am ET SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to ...

Core Insights - Boundless Bio is focused on developing therapies for oncogene-amplified cancers, with ongoing clinical trials and promising data expected in the near future [2][3][7] Research and Development Highlights - The BBI-355 Phase 1/2 POTENTIATE trial is currently enrolling patients, with initial proof-of-concept data anticipated in the second half of 2025 [1][3] - A novel Kinesin program is on track for a development candidate nomination by mid-2025, with an IND filing planned for the first half of 2026 [1][4] - Preclinical data for the RNR inhibitor BBI-825 suggests it may delay or prevent acquired resistance in colorectal cancer models [5] Financial Performance - As of March 31, 2025, the company reported a cash position of $138.3 million, providing operational runway into 2027 [1][8] - Research and Development expenses for Q1 2025 were $12.1 million, a decrease from $13.1 million in Q1 2024 [8][12] - General and Administrative expenses increased to $5.2 million in Q1 2025 from $3.8 million in Q1 2024 [8][12] - The net loss for Q1 2025 was $15.8 million, compared to a net loss of $15.4 million in the same period of 2024 [8][12]

Core Insights - Boundless Bio is advancing its clinical-stage oncology programs, particularly BBI-355, an oral CHK1 inhibitor, with preliminary proof-of-concept data expected in the second half of 2025 [1][2][6] - The company is also progressing a novel Kinesin program aimed at targeting ecDNA segregation, with a development candidate nomination anticipated by mid-2025 and an IND submission planned for the first half of 2026 [1][4][6] Research and Development Highlights - BBI-355 is designed to address replication stress in oncogene-amplified cancers and is currently in a Phase 1/2 POTENTIATE trial [3][6] - The Kinesin program is in preclinical development, focusing on a previously undrugged kinesin essential for ecDNA segregation during cell division [6] Financial Performance - As of December 31, 2024, Boundless Bio reported a cash position of $152.1 million, which is expected to support operations into 2027 [1][7] - Research and Development (R&D) expenses for Q4 2024 were $13.3 million, and for the full year, they totaled $55.3 million, compared to $10.4 million and $42.6 million for the same periods in 2023 [7][8] - General and Administrative (G&A) expenses for Q4 2024 were $5.0 million, with a total of $18.0 million for the full year, up from $3.4 million and $12.2 million in 2023 [7] Corporate Developments - In February 2025, Boundless Bio appointed Robert Doebele, M.D., Ph.D., as Chief Medical Officer, who has extensive experience in oncology program development [4]